目的:本研究旨在探索Withaniasomnifera/ashwagandha根提取物(ARE)减轻健康老年犬年龄相关变化的临床潜力。我们假设ARE可以减少年龄增长的影响,包括生理变化,免疫反应下降和对疾病的易感性,通过其免疫调节作用。
方法:随机,双盲,安慰剂对照试验在Telangana进行,印度,从2022年7月到2022年9月。二十只看起来健康的狗,8岁或以上,已注册。将狗分为两组接受ARE(15mg/kg,每天一次,口服)或安慰剂对照。各种参数,包括血清皮质醇水平,血液学资料,生化标志物,抗氧化指标和抗炎反应,在研究开始时进行评估,第30天和第60天。
结果:ARE组红细胞计数和血红蛋白水平显著增加(p<0.001),而白细胞计数下降(p<0.05)。此外,肝功能的重要标志物显著降低(丙氨酸转氨酶,天冬氨酸转氨酶,白蛋白和球蛋白;第60天p<0.001),以及肾功能标志物(肌酐和血尿素氮;第30天和第60天p<0.001),与安慰剂对照组相比,在ARE治疗的狗中观察到。此外,氧化应激标志物的水平(超氧化物歧化酶,过氧化氢酶,谷胱甘肽和丙二醛)被ARE干预显着调节,表明很强的抗氧化作用。有趣的是,ARE组血清皮质醇水平显著降低(p<0.001)。与基线相比,是显著降低关键炎症标志物,包括干扰素-γ,肿瘤坏死因子-α,第60天活化B细胞的核因子κ轻链增强剂和白介素-10(p<0.001)水平。
结论:结论:这项研究的结果表明,通过改善血液学和生化特征,ARE在健康的老年犬中具有适应性,增强抗氧化防御,减少压力和调节炎症反应。
OBJECTIVE: This study aimed to explore the clinical potential of
Withania somnifera/ashwagandha root extract (ARE) to mitigate age-related changes in healthy geriatric dogs. We hypothesized that ARE can reduce the effects of advancing age, including physiological changes, immune response decline and susceptibility to diseases, by its immunomodulatory effects.
METHODS: A randomized, double-blind, placebo-controlled trial was conducted in Telangana, India, from July 2022 to September 2022. Twenty apparently healthy dogs, aged 8 years or older, were enrolled. The dogs were divided into two groups to receive ARE (15 mg/kg, once daily, orally) or a placebo control. Various parameters, including serum cortisol levels, haematological profiles, biochemical markers, antioxidant indicators and anti-inflammatory responses, were assessed at the initiation of study, day 30, and day 60.
RESULTS: The erythrocyte count and haemoglobin levels were significantly increased with ARE (p < 0.001), whereas leukocyte count decreased (p < 0.05). Moreover, significant decreases in important markers of liver function (alanine aminotransferase, aspartate aminotransferase, albumin and globulin; p < 0.001 at day 60), as well as kidney function markers (creatinine and blood urea nitrogen; p < 0.001 at days 30 and 60), were observed in ARE-treated dogs compared to the placebo control group. In addition, the levels of markers of oxidative stress (superoxide dismutase, catalase, glutathione and malondialdehyde) were significantly modulated by ARE intervention, indicating strong antioxidant effects. Interestingly, serum cortisol levels reduced significantly with ARE (p < 0.001). Compared to baseline, ARE significantly decreased key inflammatory markers, including interferon-γ, tumour necrosis factor-α, nuclear factor kappa light chain enhancer of activated B cells and interleukin-10 (p < 0.001) levels at day 60.
CONCLUSIONS: In conclusion, the findings of this study suggest that ARE has adaptogenic properties in healthy geriatric dogs by improving haematological and biochemical profiles, enhancing antioxidant defence, reducing stress and modulating inflammatory responses.